| Drug Name: | Procarbazine (671-16-9) |
|---|---|
| PubChem ID: | 4915 |
| SMILES: | CC(C)NC(=O)C1=CC=C(C=C1)CNNC |
| InchiKey: | CPTBDICYNRMXFX-UHFFFAOYSA-N |
| Therapeutic Category: | Antineoplastic Agents |
| Molecular Weight (dalton) | : | 221.304 |
| LogP | : | 1.0488 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 3 |
| Hydrogen Bond Donor Count | : | 3 |
| Total Polar Surface Area | : | 53.16 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Phenytoin (57-41-0) | Hypersensitivity | Synergistic | enzyme-inducing antiepileptics may increase the metabolism of procarbazine to metabolites | Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors |
| Prochlorperazine (58-38-8) | Dystonic Reaction | Synergistic | Prochlorperazine was thought to have contributed to the sedative effects of procarbazine | Procarbazine-prochlorperazine interaction: an underreported phenomenon |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category